Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of peer-reviewed Phase 1 data for TNX-1500, its investigational anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study, conducted in healthy volunteers, demonstrated favorable safety, tolerability, and pharmacodynamic results, paving the way for a planned Phase 2 investigator-initiated study in kidney transplant rejection in the second half of 2026, pending FDA clearance.
The Phase 1 study found that TNX-1500 was generally well tolerated with no serious adverse events. It showed sustained suppression of T cell-dependent antibody responses and a half-life supporting monthly intravenous dosing. These results are critical for the drug's potential as a prophylactic treatment for transplant rejection, a significant unmet medical need. The advancement into Phase 2 could offer a new option for kidney transplant patients, potentially improving graft survival and reducing the burden of current immunosuppressive regimens.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) for fibromyalgia represents the first new treatment for the condition in over 15 years. Tonix's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond CNS, Tonix's immunology pipeline includes TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The publication of these data marks a significant step forward for Tonix, as it moves TNX-1500 into later-stage clinical development. For the industry, the favorable profile of TNX-1500 could represent a novel approach to preventing transplant rejection, potentially offering improved safety and convenience over existing therapies. For patients, this could mean more effective and tolerable treatment options, ultimately improving outcomes for kidney transplant recipients. The planned Phase 2 study will be closely watched by the medical community and investors alike.
For more information on Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP. The full press release can be accessed at https://ibn.fm/DHiKX.
